Pharmacokinetics, Excretion, and Metabolism of [14C]CK-4021586 Following Single Oral Administration to Rats

Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

Association of Sociodemographic Characteristics and Healthcare Costs in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

AMBER-HFpEF: Assessment of CK-586 in a Multicenter, Blinded Evaluation of Safety and Tolerability Results in HFpEF

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: A 96-week Analysis From FOREST-HCM

Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM

Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM

Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM